Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Selective synthetic ligands for FFA1-4 receptors have been developed as potential treatments for Type 2 Diabetes (T2D). Evidence indicates that FFA1-4 agonists increase insulin sensitivity, induces body mass loss, reduces inflammation, and has beneficial metabolic effects.
However, there are no FDA‑ or EMA‑approved free fatty acid (FFA) receptor agonists specifically indicated for the treatment of type 2 diabetes (T2D).
see also:
[Fatty Acids & Incretins](brain://PcaA7Uv43UGHIO4…